EUVIMEDEUVIMED entdecken
Vergleichsstudie

Adverse Event Profile Differences Between Metyrapone and Osilodrostat: A Pharmacovigilance Study of the FDA Adverse Event Reporting System

Chunyong Xia iD, Lanxin Hu, Ying Fan, Jie Liu, Ya Gan

Hormone and Metabolic Research · 2025-08 · 57 (08) · 464-470

DOI: 10.1055/a-2685-7512 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Hormone and Metabolic Research, online erschienen am 18.09.2025. Verfasst von Chunyong Xia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Chongqing University Jiangjin Hospital, Chongqing, China. Hauptthemen laut MEDLINE: Metyrapone, Imidazoles, Pyridines, Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing, China, Scientific Research cultivation project of Chongqing University Jiangjin Hospital, Outstanding Young Medical Talents Program of Chongqing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metyrapone and osilodrostat are both steroidogenic inhibitors targeting the 11β-hydroxylase, yet their safety profile has not been comprehensively analyzed. The objective of this study is to compare the adverse events (AEs) associated with osilodrostat and metyrapone based on the Food and Drug Administration Adverse Event Reporting System (FAERS). AEs were classified according to the System Organ Class (SOC) in the Medical Dictionary for Regulatory Activities (MedDRA) version 26.1. Adverse event (AE) signals of osilodrostat and metyrapone were determined by calculating reporting odds ratios (ROR). A total of 1380 and 449 AE reports were retrieved from osilodrostat and metyrapone, respectively, involving 26 and 27 SOC categories. Unexpected AEs such as asthenia, decrease of blood potassium, myalgia, increase of blood pressure, abdominal distension, increase of blood testosterone, nephrolithiasis, and hunger were associated with osilodrostat. while metyrapone was linked with respiratory failure, deep vein thrombosis, interstitial lung disease, liver function test abnormal, and respiratory distress. Among osilodrostat-treated patients, those aged between 18 to 65 years old were more likely to develop adrenal insufficiency, fatigue, tachycardia, than those older than 65. Male patients treated with metyrapone have the significantly higher incidence of the increased blood corticotrophin, muscular weakness and acute respiratory distress syndrome compared to females. During treatment with osilodrostat and metyrapone, clinicians need to monitor the effects of AEs varied by gender and age and to pay more attention to new AE signals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetyraponeImidazolesPyridinesEnzyme InhibitorsPharmacovigilanceAdverse Drug Reaction Reporting SystemsSteroid 11-beta-HydroxylaseUnited States Food and Drug AdministrationUnited StatesHumansMaleFemaleAdolescentYoung AdultAdultMiddle AgedAgedAge FactorsSex Factors

Substanzen

MetyraponeOsilodrostatImidazolesPyridinesEnzyme InhibitorsSteroid 11-beta-Hydroxylase

Autor:innen und Institutionen

  • Department of Pharmacy, Chongqing University Jiangjin Hospital, Chongqing, China.
  • Department of Pharmacy, Guang'an People's Hospital, Sichuan, China.

ORCID-Profile: Chunyong Xia

Förderung

  • Natural Science Foundation of Chongqing, China
  • Scientific Research cultivation project of Chongqing University Jiangjin Hospital
  • Outstanding Young Medical Talents Program of Chongqing

Zitieren

APA

Xia, C., Hu, L., Fan, Y., Liu, J., & Gan, Y. (2025). Adverse Event Profile Differences Between Metyrapone and Osilodrostat: A Pharmacovigilance Study of the FDA Adverse Event Reporting System. Hormone and Metabolic Research, 57(08), 464-470. https://doi.org/10.1055/a-2685-7512

Vancouver

Xia C, Hu L, Fan Y, Liu J, Gan Y. Adverse Event Profile Differences Between Metyrapone and Osilodrostat: A Pharmacovigilance Study of the FDA Adverse Event Reporting System. Hormone and Metabolic Research. 2025;57(08):464-470. doi:10.1055/a-2685-7512

BibTeX
@article{Xia2025,
  author = {Xia, Chunyong and Hu, Lanxin and Fan, Ying and Liu, Jie and Gan, Ya},
  title = {Adverse Event Profile Differences Between Metyrapone and Osilodrostat: A Pharmacovigilance Study of the FDA Adverse Event Reporting System},
  journal = {Hormone and Metabolic Research},
  year = {2025},
  volume = {57},
  number = {08},
  pages = {464--470},
  doi = {10.1055/a-2685-7512}
}
Kostenlos starten →